ADAR1 Capital Management, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), ADAR1 Capital Management, LLC reported 196 stock positions worth $1.0 billion. Its top holding was Abivax SA-ADR (ABVX) at 11.4% of the portfolio, followed by Keros Therapeutics (KROS, 8.5%) and Protagonist Therapeutics (PTGX, 6.6%). Compared with Q2 2025, it opened 47 new positions, sold out of 43, added to 67 and reduced 50. The biggest buy was Immunovant (IMVT, shares +319%) and the biggest sale Prothena (PRTA, shares −56%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $1.0B (Q3 2025)
- SEC Filing
- 0001940272-25-000008 ↗ filed Nov 14, 2025
Holdings Value
Holdings 196 stocks · $1.0B
| ABVX Abivax SA-ADR | 11.44% | 1,350,826 | $114.7M | Reduce -56.0% |
| KROS Keros Therapeutics Inc. | 8.50% | 5,389,264 | $85.3M | No change |
| PTGX Protagonist Therapeutics Inc. | 6.55% | 989,182 | $65.7M | Add +4.3% |
| ROIV Roivant Sciences Ltd. | 5.05% | 3,347,501 | $50.6M | Add +72.5% |
| BOXX Alpha Architect 1-3 MNTH Box | 3.83% | 337,125 | $38.4M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 3.63% | 54,684 | $36.4M | Add +141.1% |
| IMVT Immunovant Inc. | 3.60% | 2,241,753 | $36.1M | Add +319.0% |
| ETNB 89BIO Inc. | 3.10% | 2,113,153 | $31.1M | Add +141.2% |
| ZLAB Zai Lab Ltd.-ADR | 2.94% | 868,780 | $29.4M | Add +2.2% |
| CYTK Cytokinetics Inc. | 2.84% | 518,921 | $28.5M | Reduce -10.9% |
| SEPN Septerna Inc. | 2.21% | 1,176,491 | $22.1M | Add +38.9% |
| PRTA Prothena Corp. PLC | 1.43% | 1,469,098 | $14.3M | Reduce -56.5% |
| BBIO Bridgebio Pharma Inc. | 1.42% | 273,414 | $14.2M | Add +5.3% |
| ABUS Arbutus Biopharma Corp. | 1.31% | 2,903,226 | $13.2M | Add +2.7% |
| RAPT Rapt Therapeutics Inc. | 1.31% | 507,771 | $13.1M | Reduce -35.2% |
| CTMX Cytomx Therapeutics Inc. | 1.29% | 4,045,414 | $12.9M | Add +31.3% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 1.24% | 135,585 | $12.4M | No change |
| AMLX Amylyx Pharmaceuticals Inc. | 1.17% | 866,202 | $11.8M | Reduce -28.1% |
| BIOA Bioage Labs Inc. | 1.10% | 1,880,073 | $11.1M | Reduce -3.0% |
| MNPR Monopar Therapeutics Inc. | 1.06% | 129,999 | $10.6M | Add +28.8% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.03% | 248,368 | $10.3M | Add +367.5% |
| LXEO Lexeo Therapeutics Inc. | 1.01% | 1,531,953 | $10.2M | Add +955.7% |
| CGON CG Oncology Inc. | 1.00% | 248,917 | $10.0M | Reduce -52.4% |
| TSHA Taysha Gene Therapies Inc. | 0.92% | 2,835,680 | $9.3M | Reduce -5.8% |
| REGN Regeneron Pharmaceuticals | 0.88% | 15,700 | $8.8M | Add +367.1% |
| IONS Ionis Pharmaceuticals Inc. | 0.87% | 133,818 | $8.8M | Reduce -9.9% |
| JANX Janux Therapeutics Inc. | 0.86% | 351,032 | $8.6M | Add +465.4% |
| IKT Inhibikase Therapeutics Inc. | 0.85% | 5,247,603 | $8.5M | Add +2.5% |
| IVVD Invivyd Inc. | 0.81% | 7,370,987 | $8.1M | New |
| MTSR Metsera Inc. | 0.80% | 152,521 | $8.0M | New |
| EQ Equillium Inc. | 0.79% | 5,559,988 | $8.0M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.79% | 750,000 | $7.9M | No change |
| QURE Uniqure NV | 0.78% | 133,316 | $7.8M | New |
| PCVX Vaxcyte Inc. | 0.77% | 213,064 | $7.7M | Add +117.3% |
| RZLT Rezolute Inc. | 0.77% | 815,975 | $7.7M | Reduce -17.5% |
| XENE Xenon Pharmaceuticals Inc. | 0.76% | 189,098 | $7.6M | Reduce -27.1% |
| ASND Ascendis Pharma A/S | 0.72% | 36,345 | $7.2M | Add +2492.4% |
| SVRA Savara Inc. | 0.71% | 1,988,288 | $7.1M | Reduce -44.8% |
| SRPT Sarepta Therapeutics Inc. | 0.67% | 349,807 | $6.7M | Add +66.3% |
| RVMD Revolution Medicines Inc. | 0.65% | 139,136 | $6.5M | Add +3.7% |
| AAM Aa Mission Acquisition Cor-A | 0.61% | 578,359 | $6.1M | No change |
| BBOT Bridgebio Oncology Therapeut | 0.58% | 501,228 | $5.8M | New |
| VRNA Verona Pharma Ltd. | 0.55% | 51,450 | $5.5M | Add +80.8% |
| OACCU Oaktree Acquisition III Life | 0.55% | 516,482 | $5.5M | No change |
| TEVA Teva Pharmaceutical-SP ADR | 0.54% | 267,816 | $5.4M | Reduce -22.6% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.50% | 49,571 | $5.0M | Add +9.2% |
| ATAIBECKLEY INC filed as ATAI LIFE SCIENCES NV | 0.48% | 913,242 | $4.8M | New |
| UTHR United Therapeutics Corp. | 0.47% | 11,200 | $4.7M | New |
| VKTX Viking Therapeutics Inc. | 0.46% | 175,919 | $4.6M | Add +159.4% |
| REPL Replimune Group Inc. | 0.41% | 978,894 | $4.1M | Add +9312.4% |
| NKTR Nektar Therapeutics | 0.41% | 72,007 | $4.1M | Add +355.9% |
| ESTA Establishment Labs Holdings | 0.37% | 90,688 | $3.7M | Add +262.8% |
| SNY Sanofi-ADR | 0.35% | 74,212 | $3.5M | Add +642.1% |
| KRYS Krystal Biotech Inc. | 0.33% | 18,523 | $3.3M | New |
| NAMS Newamsterdam Pharma Co. NV | 0.32% | 114,359 | $3.3M | Add +1.8% |
| FULC Fulcrum Therapeutics Inc. | 0.31% | 341,612 | $3.1M | Add +540.3% |
| MRUS Merus NV | 0.31% | 33,313 | $3.1M | Add +81.9% |
| MLYS Mineralys Therapeutics Inc. | 0.30% | 78,238 | $3.0M | Reduce -74.1% |
| KNSA Kiniksa Pharmaceuticals Inte | 0.29% | 75,187 | $2.9M | Add +33.0% |
| CLDX Celldex Therapeutics Inc. | 0.28% | 109,442 | $2.8M | Add +90.5% |
| ZURA Zura Bio Ltd. | 0.28% | 652,154 | $2.8M | Reduce -34.6% |
| VRTX Vertex Pharmaceuticals Inc. | 0.27% | 7,000 | $2.7M | New |
| ACLX Arcellx Inc. | 0.26% | 31,484 | $2.6M | Add +125.5% |
| BIIB Biogen Inc. | 0.25% | 18,000 | $2.5M | Add +252.9% |
| DCTH Delcath Systems Inc. | 0.24% | 224,385 | $2.4M | Add +50.2% |
| RNAM Avidity Biosciences Inc. | 0.23% | 53,656 | $2.3M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 0.22% | 4,895 | $2.2M | Add +364.4% |
| ASPC A Spac III Acquisition Class A | 0.22% | 215,000 | $2.2M | No change |
| MASI Masimo Corp. | 0.22% | 15,000 | $2.2M | New |
| VRDN Viridian Therapeutics Inc. | 0.22% | 101,704 | $2.2M | Reduce -40.4% |
| SMMT Summit Therapeutics Inc. | 0.21% | 102,969 | $2.1M | Add +758.1% |
| CDTX Cidara Therapeutics Inc. | 0.21% | 21,522 | $2.1M | No change |
| RGNX Regenxbio Inc. | 0.20% | 205,409 | $2.0M | Reduce -1.2% |
| KRRO Korro Bio Inc. | 0.19% | 40,235 | $1.9M | Reduce -41.5% |
| RCKT Rocket Pharmaceuticals Inc. | 0.19% | 575,800 | $1.9M | Add +108.8% |
| OABI Omniab Inc. | 0.17% | 1,090,628 | $1.7M | Add +234.4% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.17% | 49,800 | $1.7M | Reduce -9.8% |
| SLNO Soleno Therapeutics Inc. | 0.17% | 25,230 | $1.7M | Add +45.6% |
| DVAX Dynavax Technologies Corp. | 0.17% | 170,000 | $1.7M | No change |
| ALKS Alkermes PLC | 0.17% | 56,200 | $1.7M | Add +24.9% |
| GLUE Monte Rosa Therapeutics Inc. | 0.16% | 215,752 | $1.6M | New |
| MRK Merck & Co. Inc. | 0.16% | 18,540 | $1.6M | Add +163.3% |
| CCIIU Cohen Circle Acquisition Cor | 0.15% | 150,000 | $1.5M | New |
| ABOS Acumen Pharmaceuticals Inc. | 0.15% | 891,183 | $1.5M | Reduce -2.7% |
| XNCR Xencor Inc. | 0.15% | 128,865 | $1.5M | Add +50.1% |
| AGIO Agios Pharmaceuticals Inc. | 0.15% | 37,000 | $1.5M | Add +3.1% |
| WW WW International Inc.-New filed as WW INTL INC | 0.14% | 52,450 | $1.4M | New |
| ATXS Astria Therapeutics Inc. | 0.14% | 193,934 | $1.4M | Reduce -22.3% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.13% | 53,666 | $1.3M | Reduce -81.9% |
| QUINCE THERAPEUTICS INC | 0.13% | 775,034 | $1.3M | Add +442.1% |
| PFE Pfizer Inc. | 0.11% | 44,400 | $1.1M | Add +12.7% |
| MLTX Moonlake Immunotherapeutics | 0.11% | 151,495 | $1.1M | Add +341.5% |
| GRCE Grace Therapeutics Inc. | 0.10% | 350,450 | $1.0M | Add +98.4% |
| NUVL Nuvalent Inc. Class A | 0.10% | 11,842 | $1.0M | No change |
| BSAAU Best Spac I Acquisition Corp. | 0.10% | 100,000 | $1.0M | No change |
| EA Electronic Arts Inc. | 0.10% | 4,936 | $996K | New |
| BNTX Biontech SE-ADR | 0.10% | 10,000 | $986K | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.09% | 77,961 | $916K | Reduce -53.3% |
| AVR Anteris Technologies Global | 0.09% | 197,615 | $889K | Reduce -62.8% |
| TECX Tectonic Therapeutic Inc. | 0.09% | 56,007 | $879K | Reduce -23.8% |
Options reported separately and not counted above: SPY puts ($30.3M), QURE calls ($11.7M), AAM calls ($4.3M), XBI puts ($4.0M), KVACF calls ($863K), URGN calls ($798K), FULC calls ($690K), NVCR calls ($388K), BHVN calls ($375K), DYN calls ($253K), OLMA calls ($245K), REPL calls ($210K), and 6 more.
Other holdings (3): bonds, preferreds, convertibles and warrants · $2.9M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 20,000 | $2.8M | Reduce -99.0% |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 45,000 | $44K | Reduce -99.0% |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $41K | No change |
Total filed on the 13F, all lines: $1.0B.
Portfolio Sells Q2 2025 → Q3 2025
| PRTA Prothena Corp. PLC | Reduce -56.5% | 1.43% | −1.93 |
| CGON CG Oncology Inc. | Reduce -52.4% | 1.00% | −1.23 |
| SAGE Sage Therapeutics Inc. | Sold out | 0.00% | −1.08 |
| VERV Verve Therapeutics Inc. | Sold out | 0.00% | −0.86 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.77 |
| SHY iShares 1-3 Year Treasury Bo | Sold out | 0.00% | −0.73 |
| SVRA Savara Inc. | Reduce -44.8% | 0.71% | −0.64 |
| ARDX Ardelyx Inc. | Sold out | 0.00% | −0.59 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -27.1% | 0.76% | −0.58 |
| THRD Third Harmonic Bio Inc. | Sold out | 0.00% | −0.56 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -81.9% | 0.13% | −0.51 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -22.6% | 0.54% | −0.41 |
| ALEC Alector Inc. | Sold out | 0.00% | −0.40 |
| MLYS Mineralys Therapeutics Inc. | Reduce -74.1% | 0.30% | −0.38 |
| CRMD Cormedix Inc. | Sold out | 0.00% | −0.35 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −0.32 |
| CYTK Cytokinetics Inc. | Reduce -10.9% | 2.84% | −0.31 |
| AKRO Akero Therapeutics Inc. | Reduce -81.5% | 0.03% | −0.26 |
| AVR Anteris Technologies Global | Reduce -62.8% | 0.09% | −0.24 |
| ORKA Oruka Therapeutics Inc. | Reduce -85.4% | 0.04% | −0.22 |
| TSHA Taysha Gene Therapies Inc. | Reduce -5.8% | 0.92% | −0.22 |
| BIOA Bioage Labs Inc. | Reduce -3.0% | 1.10% | −0.21 |
| VIR Vir Biotechnology Inc. | Sold out | 0.00% | −0.21 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| VRDN Viridian Therapeutics Inc. | Reduce -40.4% | 0.22% | −0.17 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.16 |
| ALDX Aldeyra Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| SRRK Scholar Rock Holding Corp. | Reduce -49.4% | 0.07% | −0.16 |
| TECX Tectonic Therapeutic Inc. | Reduce -23.8% | 0.09% | −0.15 |
| KVACF Keen Vision Acquisition Corp. | Sold out | 0.00% | −0.14 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| TENX Tenax Therapeutics Inc. | Reduce -65.7% | 0.04% | −0.11 |
| SGRY Surgery Partners Inc. | Reduce -50.0% | 0.04% | −0.10 |
| VTGN Vistagen Therapeutics Inc. | Reduce -73.1% | 0.04% | −0.10 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| KALA Kala Bio Inc. | Reduce -5.2% | 0.02% | −0.10 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -28.1% | 1.17% | −0.09 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -9.9% | 0.87% | −0.09 |
| ARVN Arvinas Inc. | Reduce -35.9% | 0.07% | −0.09 |
| RGNX Regenxbio Inc. | Reduce -1.2% | 0.20% | −0.08 |
| ATXS Astria Therapeutics Inc. | Reduce -22.3% | 0.14% | −0.08 |
| NETD Nabors Energy Transition C-A | Sold out | 0.00% | −0.07 |
| NTRA Natera Inc. | Sold out | 0.00% | −0.07 |
| KZR Kezar Life Sciences Inc. | Reduce -15.2% | 0.05% | −0.06 |
| PYPD Polypid Ltd. | Sold out | 0.00% | −0.06 |
| STOK Stoke Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -32.4% | 0.05% | −0.05 |
| SPRO Spero Therapeutics Inc. | Reduce -19.7% | 0.02% | −0.05 |
| TARA Protara Therapeutic Inc. | Reduce -71.3% | 0.02% | −0.05 |
| AVTX Avalo Therapeutics Inc. | Reduce -69.1% | 0.04% | −0.04 |
Portfolio Buys Q2 2025 → Q3 2025
| IMVT Immunovant Inc. | Add +319.0% | 3.60% | +2.20 |
| ETNB 89BIO Inc. | Add +141.2% | 3.10% | +1.69 |
| ROIV Roivant Sciences Ltd. | Add +72.5% | 5.05% | +1.46 |
| SPY SS SPDR S&P 500 ETF Trust-US | Add +141.1% | 3.63% | +1.33 |
| LXEO Lexeo Therapeutics Inc. | Add +955.7% | 1.01% | +0.92 |
| IVVD Invivyd Inc. | New | 0.81% | +0.81 |
| MTSR Metsera Inc. | New | 0.80% | +0.80 |
| EQ Equillium Inc. | New | 0.79% | +0.79 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +367.5% | 1.03% | +0.78 |
| QURE Uniqure NV | New | 0.78% | +0.78 |
| SEPN Septerna Inc. | Add +38.9% | 2.21% | +0.74 |
| ASND Ascendis Pharma A/S | Add +2492.4% | 0.72% | +0.68 |
| JANX Janux Therapeutics Inc. | Add +465.4% | 0.86% | +0.62 |
| REGN Regeneron Pharmaceuticals | Add +367.1% | 0.88% | +0.59 |
| BBOT Bridgebio Oncology Therapeut | New | 0.58% | +0.58 |
| ATAIBECKLEY INC | New | 0.48% | +0.48 |
| UTHR United Therapeutics Corp. | New | 0.47% | +0.47 |
| MNPR Monopar Therapeutics Inc. | Add +28.8% | 1.06% | +0.47 |
| REPL Replimune Group Inc. | Add +9312.4% | 0.41% | +0.39 |
| NKTR Nektar Therapeutics | Add +355.9% | 0.41% | +0.34 |
| KRYS Krystal Biotech Inc. | New | 0.33% | +0.33 |
| VRTX Vertex Pharmaceuticals Inc. | New | 0.27% | +0.27 |
| SNY Sanofi-ADR | Add +642.1% | 0.35% | +0.27 |
| FULC Fulcrum Therapeutics Inc. | Add +540.3% | 0.31% | +0.25 |
| PCVX Vaxcyte Inc. | Add +117.3% | 0.77% | +0.24 |
| RNAM Avidity Biosciences Inc. | New | 0.23% | +0.23 |
| MASI Masimo Corp. | New | 0.22% | +0.22 |
| ESTA Establishment Labs Holdings | Add +262.8% | 0.37% | +0.20 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +364.4% | 0.22% | +0.17 |
| SMMT Summit Therapeutics Inc. | Add +758.1% | 0.21% | +0.17 |
| VKTX Viking Therapeutics Inc. | Add +159.4% | 0.46% | +0.17 |
| GLUE Monte Rosa Therapeutics Inc. | New | 0.16% | +0.16 |
| MRUS Merus NV | Add +81.9% | 0.31% | +0.15 |
| CCIIU Cohen Circle Acquisition Cor | New | 0.15% | +0.15 |
| BIIB Biogen Inc. | Add +252.9% | 0.25% | +0.15 |
| WW WW International Inc.-New | New | 0.14% | +0.14 |
| CTMX Cytomx Therapeutics Inc. | Add +31.3% | 1.29% | +0.14 |
| ACLX Arcellx Inc. | Add +125.5% | 0.26% | +0.11 |
| VRNA Verona Pharma Ltd. | Add +80.8% | 0.55% | +0.11 |
| EA Electronic Arts Inc. | New | 0.10% | +0.10 |
| BNTX Biontech SE-ADR | New | 0.10% | +0.10 |
| CLDX Celldex Therapeutics Inc. | Add +90.5% | 0.28% | +0.09 |
| QUINCE THERAPEUTICS INC | Add +442.1% | 0.13% | +0.09 |
| SRPT Sarepta Therapeutics Inc. | Add +66.3% | 0.67% | +0.08 |
| OABI Omniab Inc. | Add +234.4% | 0.17% | +0.08 |
| RCKT Rocket Pharmaceuticals Inc. | Add +108.8% | 0.19% | +0.08 |
| ACRS Aclaris Therapeutics Inc. | New | 0.07% | +0.07 |
| LITS Lite Strategy Inc. | New | 0.07% | +0.07 |
| DAY Dayforce Inc. | New | 0.07% | +0.07 |
| SUPN Supernus Pharmaceuticals Inc. | New | 0.07% | +0.07 |
Options Activity Q2 2025 → Q3 2025
| SPY SS SPDR S&P 500 ETF Trust-US | put | Add +12.3% | 45,500 | $30.3M |
| QURE Uniqure NV | call | New | 200,000 | $11.7M |
| JANX Janux Therapeutics Inc. | call | Sold out | 264,900 | $6.1Mbefore exit |
| AAM Aa Mission Acquisition Cor-A | call | New | 405,089 | $4.3M |
| XBI SS SPDR S&P Biotech ETF | put | New | 40,000 | $4.0M |
| SMMT Summit Therapeutics Inc. | call | Sold out | 100,000 | $2.1Mbefore exit |
| SRPT Sarepta Therapeutics Inc. | call | Sold out | 55,000 | $941Kbefore exit |
| NKTR Nektar Therapeutics | put | Sold out | 35,000 | $904Kbefore exit |
| KVACF Keen Vision Acquisition Corp. | call | New | 75,000 | $863K |
| URGN Urogen Pharma Ltd. | call | New | 40,000 | $798K |
| FULC Fulcrum Therapeutics Inc. | call | New | 75,000 | $690K |
| NVCR Novocure Ltd. | call | New | 30,000 | $388K |
| INMB Inmune Bio Inc. | put | Sold out | 130,200 | $301Kbefore exit |
| OLMA Olema Pharmaceuticals Inc. | call | New | 25,000 | $245K |
| REPL Replimune Group Inc. | call | New | 50,000 | $210K |
| ATYR Atyr Pharma Inc. | put | Add +345.0% | 222,500 | $161K |
| GOSS Gossamer Bio Inc. | call | New | 55,100 | $145K |
| MLTX Moonlake Immunotherapeutics | call | New | 17,000 | $122K |
| IOVA Iovance Biotherapeutics Inc. | call | New | 50,000 | $109K |
| STI Solidion Technology Inc. | call | New | 13,500 | $63K |
| ATYR Atyr Pharma Inc. | call | New | 84,800 | $61K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2025 → Q3 2025
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | Reduce -99.0% | 20,000 | $2.8M |
| AAM.WS Aa Mission Acquisition -30 | *W EXP 08/01/203 | Sold out | 505,099 | $50Kbefore exit |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | Reduce -99.0% | 45,000 | $44K |
| JVSAR Jvspac Acquisition Corp.-RTS | RIGHT 11/26/2026 | Sold out | 24,000 | $21Kbefore exit |
| IROHR Iron Horse Acquisitions Righ | RIGHT 99/99/9999 | Sold out | 12,320 | $6Kbefore exit |
| KVAWF Keen Vision Acquisition C-28 | *W EXP 03/15/202 | Sold out | 75,000 | $4Kbefore exit |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | Sold out | 13,144 | $2Kbefore exit |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | Sold out | 18,000 | $360before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |